In addition, EpoY decreased xenograft tumor growth by suppressing LUSC cell proliferation and tumor angiogenesis, indicated by the levels of proliferative Ki67+ cells and the microvessel density of CD31 (Fig. S2). Here, MKI67 is linked to neoplasm.